Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGAZUS: Cabazitaxel with PEG-G-CSF in mCRPC
NCT02441894Phase 4Completed
- Sponsor
- Sanofi
- Start
- Apr 2015
- Primary completion
- Feb 2016
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cabazitaxel ginsenoside liposome injection in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sanofi. Primary endpoint: Incidence of Febrile Neutropenia during Cycle 1. Started Apr 2015; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02441894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02441894.